Moleculin Announces First European Approval for Phase 3 AML Trial
HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...
Moleculin Biotech receives first approval in Europe for AML trial recruiting
Moleculin Biotech (MBRX) has received first country regulatory approval in Europe to begin recruiting for its Phase 3 pivotal trial protocol ...
IFLScience2d
Montana Considers Becoming First US State To Ban mRNA Vaccine Use
O n Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA vaccines in humans. The bill was sponsored by State Representative Greg Kmetz ...
PharmiWeb2d
Pharmaceutical Market: Shaping the Future of Healthcare and Medicine
Pharmaceutical Market Size and Growth 2025 to 2034The global pharmaceutical market size was valued at USD 1,607.07 billion in ...
El País in English4d
‘The tsetse fly is attracted to the color blue’: How Guinea has managed to eliminate sleeping sickness as a public health problem
A comprehensive strategy that combines pharmacological advances, vector control, public outreach to raise awareness and ...
PharmiWeb5d
New England Journal of Medicine publishes new data…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...